Industries > Pharma > Pharmaceutical Contract Manufacturing Market 2018-2028

Pharmaceutical Contract Manufacturing Market 2018-2028

Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

PUBLISHED: 27 June 2018
PAGES: 230
PRODUCT CODE: PHA0321
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The API Manufacturing submarket held 66% of the market in 2017. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $93bn in 2022.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 230-page report you will receive 77 tables and 58 figures– all unavailable elsewhere.

The 230-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Pharmaceutical Contract Manufacturing Market forecasts from 2018-2028

• Submarket forecasts at world level, from 2018-2028:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

• Revenue forecasts from 2018-2028, for these regional and national markets:
• The US
• Canada
• Japan
• EU5: Germany, France, the UK, Italy and Spain
• BRIC: Brazil, Russia, India, China
• South Korea
• Turkey
• Mexico
• Others

Pharmaceutical Contract Manufacturing Market 2018-2028

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

• Qualitative Analysis from a CMO Perspective

• Qualitative Analysis from a Client Perspective

Visiongain’s study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2018-2028: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Latest Pharma news

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

READ

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

READ

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

READ

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

READ

Categories